Phaseline

Companies › Eluciderm

Eluciderm: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ELU42
Tankyrase inhibitor combined with derivatized hyaluronic acid (DHA77) excipient for topica
TNKSPhase 1Diabetic Foot Ulcer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07396376ELU42Phase 1Diabetic Foot UlcerMetabolic and endocrineJun 2026

Targets

TNKS (1)

Companies with the same targets

Allarity Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.